Plymouth, United Kingdom

Re-Cognition Health

Alzheimer Disease

Dementia

Cognitive Dysfunction

BI 409306

JNJ-64042056

Lanabecestat

LY3314814

Boehringer Ingelheim

AstraZeneca

Janssen (J&J Innovative Medicine)

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this study is to assess whether JNJ-64042056 affects the spread and build up of tau (a protein in brain) when compared with placebo, using brain scan (tau PET) to determine results from specific areas of the brain.

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

Re-Cognition Health | Plymouth, United Kingdom

Site insights

Work at this site?

Active trials

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease (Reτain)

Trial sponsors